Literature DB >> 28589588

Editorial: biologics in inflammatory bowel disease-time for direct comparisons.

R C Ungaro1, J-F Colombel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28589588      PMCID： PMC6350516          DOI： 10.1111/apt.14090

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  7 in total

1.  IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.

Authors:  L Vuitton; P Marteau; W J Sandborn; B G Levesque; B Feagan; S Vermeire; S Danese; G D'Haens; M Lowenberg; R Khanna; G Fiorino; S Travis; J Y Mary; L Peyrin-Biroulet
Journal:  Gut       Date:  2015-09-09       Impact factor: 23.059

Review 2.  Current and emerging therapeutic targets for IBD.

Authors:  Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-01       Impact factor: 46.802

Review 3.  Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.

Authors:  Silvio Danese; Gionata Fiorino; Laurent Peyrin-Biroulet; Ersilia Lucenteforte; Gianni Virgili; Lorenzo Moja; Stefanos Bonovas
Journal:  Ann Intern Med       Date:  2014-05-20       Impact factor: 25.391

Review 4.  Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.

Authors:  Siddharth Singh; Sushil Kumar Garg; Darrell S Pardi; Zhen Wang; Mohammad Hassan Murad; Edward V Loftus
Journal:  Mayo Clin Proc       Date:  2014-10-29       Impact factor: 7.616

Review 5.  Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.

Authors:  A Cholapranee; G S Hazlewood; G G Kaplan; L Peyrin-Biroulet; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-03-22       Impact factor: 8.171

Review 6.  Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.

Authors:  L Vuitton; L Peyrin-Biroulet; J F Colombel; B Pariente; G Pineton de Chambrun; A J Walsh; J Panes; S P L Travis; J Y Mary; P Marteau
Journal:  Aliment Pharmacol Ther       Date:  2017-01-23       Impact factor: 8.171

Review 7.  Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.

Authors:  Adrian D Vickers; Claire Ainsworth; Reema Mody; Annika Bergman; Caroline S Ling; Jasmina Medjedovic; Michael Smyth
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240
  7 in total
  2 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

2.  Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.

Authors:  Katerina Pantavou; Anneza I Yiallourou; Daniele Piovani; Despo Evripidou; Silvio Danese; Laurent Peyrin-Biroulet; Stefanos Bonovas; Georgios K Nikolopoulos
Journal:  United European Gastroenterol J       Date:  2019-10-17       Impact factor: 4.623
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.